X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-akebias-anemia-drug-2024-03-28/
https://www.prnewswire.com/news-releases/vafseo-approved-by-the-us-fda-for-the-treatment-of-anemia-due-to-chronic-kidney-disease-in-dialysis-dependent-adult-patients-302102216.html
https://www.prnewswire.com/news-releases/akebia-receives-fda-approval-of-vafseo-vadadustat-tablets-for-the-treatment-of-anemia-due-to-chronic-kidney-disease-in-adult-patients-on-dialysis-302101854.html
https://www.prnewswire.com/news-releases/akebia-therapeutics-resubmits-new-drug-application-to-the-fda-for-vadadustat-301941097.html
https://www.prnewswire.com/news-releases/akebia-announces-approval-of-vafseo-vadadustat-in-australia-and-provides-commercial-update-301938187.html
https://www.fiercepharma.com/pharma/after-high-profile-snub-akebia-plots-resubmission-vadadustat-ckd-anemia-fda
https://www.prnewswire.com/news-releases/akebia-therapeutics-completed-type-a-meeting-with-the-fda-and-expects-to-resubmit-vadadustat-nda-in-third-quarter-2023-301879162.html
https://www.prnewswire.com/news-releases/akebia-announces-swissmedic-approval-of-vafseo-vadadustat-301854778.html
https://endpts.com/akebia-to-refile-anemia-drug-vadadustat-after-fda-denied-appeal/
https://www.ema.europa.eu/en/documents/overview/vafseo-epar-medicine-overview_en.pdf
https://www.prnewswire.com/news-releases/akebia-therapeutics-enters-into-license-agreement-with-medice-arzneimittel-putter-gmbhcokg-for-the-commercialization-of-vafseo-for-the-treatment-of-anemia-associated-with-ckd-in-europe-and-australia-301834143.html
https://www.prnewswire.com/news-releases/akebia-announces-uk-mhra-approval-of-vafseo-vadadustat-for-the-treatment-of-symptomatic-anemia-associated-with-chronic-kidney-disease-in-adults-on-chronic-maintenance-dialysis-301830706.html
https://www.prnewswire.com/news-releases/akebia-receives-european-commission-approval-for-vafseo-vadadustat-for-the-treatment-of-symptomatic-anaemia-associated-with-chronic-kidney-disease-in-adults-on-chronic-maintenance-dialysis-301807286.html
https://endpts.com/akebia-touts-new-data-on-anemia-drug-a-year-after-rejection/
https://www.prnewswire.com/news-releases/akebia-therapeutics-announces-positive-top-line-results-from-vadadustat-alternative-dosing-study-301787853.html
https://www.fiercepharma.com/pharma/amid-ongoing-dispute-fda-akebia-proposes-new-dosing-oral-anemia-drug-kidney-disease
https://www.prnewswire.com/news-releases/akebia-therapeutics-provides-update-on-regulatory-process-for-vadadustat-301785315.html
https://www.fiercepharma.com/pharma/take-gsk-akebias-oral-anemia-drug-vafseo-recommended-chmp-after-fda-snub
https://www.prnewswire.com/news-releases/akebia-receives-positive-chmp-opinion-in-europe-for-vafseo-vadadustat-for-the-treatment-of-symptomatic-anaemia-associated-with-chronic-kidney-disease-in-adults-on-chronic-maintenance-dialysis-301754922.html
https://www.fiercebiotech.com/biotech/akebia-says-fda-staffing-constraints-are-throwing-roadblock-appeal-process
https://www.prnewswire.com/news-releases/akebia-therapeutics-received-interim-response-to-appeal-for-vadadustat-for-the-treatment-of-anemia-due-to-chronic-kidney-disease-from-the-fda-301709057.html
https://www.fiercebiotech.com/biotech/akebia-taking-fight-fda-months-after-approval-rejection
https://www.prnewswire.com/news-releases/akebia-therapeutics-regaining-rights-to-vadadustat-in-the-united-states-europe-china-and-access-consortium-countries-upon-termination-of-collaboration-and-license-agreements-with-otsuka-301579109.html
https://www.biospace.com/article/akebia-terminates-license-agreements-with-otsuka-for-vadadustat/
https://www.biopharmadive.com/news/akebia-layoffs-restructuring-fda-rejection/621730/
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-declines-approve-akebias-anemia-treatment-2022-03-30/
https://www.fiercepharma.com/pharma/several-companies-look-march-ahead-fda-approval-decisions-due-month
https://endpts.com/akebia-scrapes-together-85m-war-chest-to-commercialize-vada-as-pdufa-date-looms/
https://ir.akebia.com/news-releases/news-release-details/akebia-therapeutics-announces-amendment-license-agreement-vifor
https://ir.akebia.com/news-releases/news-release-details/akebia-therapeutics-announces-amendment-license-agreement-vifor
https://www.fiercebiotech.com/biotech/gsk-pulls-off-clean-sweep-endpoint-hits-anemia-phase-3-positioning-it-to-leapfrog
https://www.prnewswire.com/news-releases/akebia-announces-vadadustat-efficacy-and-safety-data-to-be-presented-at-american-society-of-nephrology-kidney-week-2021-301401831.html
https://www.fiercepharma.com/pharma/as-roxadustat-lost-fda-s-favor-akebia-ceo-touts-first-class-opening-for-its-anemia-contender
https://www.fiercepharma.com/pharma/as-roxadustat-lost-fda-s-favor-akebia-ceo-touts-first-class-opening-for-its-anemia-contender
https://www.prnewswire.com/news-releases/new-england-journal-of-medicine-publishes-results-of-global-phase-3-clinical-program-of-vadadustat-for-the-treatment-of-anemia-due-to-chronic-kidney-disease-301279608.html
https://www.biospace.com/article/releases/new-england-journal-of-medicine-publishes-results-of-global-phase-3-clinical-program-of-vadadustat-for-the-treatment-of-anemia-due-to-chronic-kidney-disease/
https://www.prnewswire.com/news-releases/akebia-presents-results-from-its-pro2tect-global-phase-3-program-of-vadadustat-for-the-treatment-of-anemia-due-to-chronic-kidney-disease-in-adult-patients-not-on-dialysis-during-late-breaking-session-at-american-society-of-nephrol-301158891.html
https://endpts.com/akebia-shares-crater-as-their-phiii-anemia-drug-fails-on-safety-offering-rival-fibrogen-a-huge-advantage/
https://www.prnewswire.com/news-releases/akebia-therapeutics-announces-top-line-results-from-its-pro2tect-global-phase-3-program-of-vadadustat-for-treatment-of-anemia-due-to-chronic-kidney-disease-in-adult-patients-not-on-dialysis-301123808.html
https://ir.akebia.com/news-releases/news-release-details/akebia-therapeutics-announces-first-commercial-launch-vafseotm
https://www.prnewswire.com/news-releases/akebia-therapeutics-announces-first-commercial-launch-of-vafseo-vadadustat-tablets-a-new-oral-treatment-for-anemia-due-to-chronic-kidney-disease-in-japan-301118420.html
https://www.prnewswire.com/news-releases/akebia-announces-initiation-of-investigator-sponsored-study-evaluating-vadadustat-for-prevention-and-treatment-of-ards-in-patients-hospitalized-with-covid-19-301092689.html
https://ir.akebia.com/news-releases/news-release-details/akebia-therapeutics-announces-approval-vadadustat-japan
https://www.nasdaq.com/articles/why-akebia-therapeutics-stock-is-crushing-it-today-2020-05-05
https://www.prnewswire.com/news-releases/akebia-announced-positive-top-line-results-from-global-phase-3-program-of-vadadustat-for-treatment-of-anemia-due-to-chronic-kidney-disease-in-adult-patients-on-dialysis-reports-first-quarter-2020-financial-results-301052863.html
https://www.biospace.com/article/releases/vifor-pharma-announces-akebia-s-positive-top-line-results-from-global-phase-iii-program-of-vadadustat-for-treatment-of-anaemia-due-to-chronic-kidney-disease-in-adult-dialysis-dependent-patients/
https://www.businesswire.com/news/home/20191109005033/en/Akebia-Announces-Positive-52-week-Efficacy-Safety-Data/?feedref=JjAwJuNHiystnCoBq_hl-WFAllVCLJFCqzlmaJ8DKHU4plfPZtlGYRDUHCSmgbii6XkLWuQZD-HgGRnjQvCyg3iCfEFIaJW7-otp9V1XQiK2eHTJy3ZqOEt7kKgLu20J
https://www.thepharmaletter.com/article/first-regulatory-filing-for-vadadustat-boosts-akebia-therapeutics
https://www.fiercebiotech.com/biotech/akebia-s-japanese-vadadustat-data-bode-well-for-larger-trials-analysts
Market Place
Share 
